Prospectively validate an antenatal bacterial vaginosis (BV) risk score at two public health department obstetrics clinics.
INTRODUCTION
Bacterial vaginosis (BV) is an infection caused by an overgrowth of Gardnerella vaginalis, mixed anaerobes, and genital mycoplasmas. 1 BV is the most common vaginal disorder in women and has been found in 6 to 32% of pregnant women worldwide, as reviewed by McGregor and French. 2 Little is known about the natural history and pathogenesis of BV. Up to 50% of BV cases are asymptomatic, based on research from the 1980s in college students and sexually transmitted disease clinic patients. 3, 4 Asymptomatic BV has been found to be associated with approximately twice the risk of preterm delivery, based on a recent meta-analysis; 5 however, clinical trials have not consistently found that treatment of asymptomatic BV reduces the frequency of preterm delivery. 6 BV increases the risk of preterm premature rupture of the membranes (PROM), amniotic fluid infection and postpartum endometritis. 2 BV has also been linked with facilitating the transmission of human immunodeficiency virus. 7 The diagnostic criteria for BV have evolved over time. In 1983, Amsel 3 established that women should be diagnosed with BV if three of the following four features were present:(a) thin, homogeneous, milky vaginal discharge, (b) fishy amine odor from KOH (''whiff'') test, (c) detection of clue cells from a saline wet mount, and (d) vaginal pH>4.5. Unfortunately, these criteria except vaginal pH are subjective and dependent on both the ability of the clinician and the equipment to identify clue cells. 8, 9 In 1991, Nugent 9 proposed a scoring system where three categories of morphotypes (Lactobacillus, Gardnerella, and Mobiluncus) are counted separately and summed to yield a single score between 0 and 10. The criterion for positive BV is a score Z7. For the last decade, this has been considered the standard method for diagnosing BV for research purposes, while individual clinics typically still use the Amsel criteria.
In current practice, the diagnosis of BV is restricted to women who complain of vaginal symptoms or who have a noticeable vaginal odor. Given that many women with BV are asymptomatic (based on nonpregnant populations), 8, 9 we estimate that approximately half the women affected are not treated.
Our prior research developed a clinical risk scoring system for antenatal BV 10 to assist clinicians in identifying antenatal BV cases without having to conduct diagnostic tests on 100% of their patients. The objective of this study was to field test this BV risk scoring system in two health department obstetrics clinics. A secondary objective was to assess the proportion of BV that is asymptomatic in pregnant women seen in public health department clinics.
MATERIALS AND METHODS
This study was implemented in two North Carolina Public Health Department Obstetrics clinics. Wake County, located in central NC, was selected as a study site based on their active participation in various research studies with the University of North Carolina at Chapel Hill. Catawba County, located in western NC, self-nominated their clinic to field test the scoring system after the underlying BV PIN Points project was recognized statewide as a 1999 Perinatal Model of Excellence. These two populations will henceforward be called Wake County and Catawba County.
All women who entered prenatal care at the two county health departments were assigned a BV risk score at their first prenatal care visit (n ¼ 525 in Wake County, and n ¼ 205 in Catawba County). The Wake County women entered prenatal care between November 1998 and March 1999, and the first prenatal care visits occurred between March 1999 and July 1999 in Catawba County. All women who were still pregnant and returned for a prenatal clinic visit around their 24th to 28th week of gestation were scored and screened a second time (n ¼ 290 in Wake County, n ¼ 146 in Catawba County). These two time periods were selected because they correspond to the two times during pregnancy that the clinics routinely conduct a pelvic examination.
We restricted our population to women who met the following criteria: dual screenings at least 4 weeks apart, first screening at or before 24 weeks of gestation, and adequate vaginal smear for assessment of BV. This resulted in n ¼ 267 women from Wake County and n ¼ 142 women from Catawba County, for a total of 409 women.
The University of North Carolina Institutional Review Board approved this study. Informed consent from individuals was not required since this risk scoring system was incorporated into the public health department's routine clinical practices.
Vaginal swabs were obtained at both risk score assessments. ''True'' BV was diagnosed as follows: A Dacron-tipped swab was used during a pelvic examination to take a sample of vaginal secretions from the junction of the upper third and lower two thirds of the lateral vaginal wall. The swab was rolled onto a glass slide and then touched to a pH strip. The slides were allowed to air dry. Smears were Gram stained and evaluated according to the Nugent method, 9 blinded to any information about the patient except pH, which was recorded on the slide. Scores of 7 to 10 were considered indicative of bacterial vaginosis, and Gram stain scores of 0 to 6 were the referent group in the analysis. BV was also diagnosed clinically using the usual Amsel criteria, 3 and women were treated or not according to those results. The Gram stain results were not determined until the end of the study. Janice French (CNMW, MS, Denver, CO, USA) scored all the vaginal smears from Wake County. A stratified sample was subsequently read and Nugent scored by the laboratory of Dr Sharon Hillier (University of Pittsburgh) for quality control purposes. For the Catawba County vaginal smears, the reverse process was used: all the slides were originally read by Dr Hillier's laboratory, with a stratified sample read by Ms French for quality control purposes. The stratified sample consisted of 5% of the normal slides, 15% of the intermediate BV slides, and 15% of the definitely BV slides. Of the 61 slides read by both labs, five slides (8.2%) resulted in a different trichotomized BV category: two slides differed by 2 points and three slides differed by 1 point. For our analysis, which used a dichotomized outcome (definite BV vs normal or intermediate flora), the potential misclassification would be 6.5% (four slides out of 61) based on the stratified sample or 3.3% after reweighting the sample to reflect the full population. The BV dichotomized diagnosis used for this analysis for all slides, including the four that differed between readers, was based on the original reading.
Below is the form used to implement the BV risk scoring system (Image 1). The risk factors and corresponding values that were implemented in the county health departments differed slightly from what was published 10 because the published risk score was
Image 1 updated with a larger database (recruitment was ongoing) after the health department implementation began. The system implemented included sickle cell/thalassemia trait or disease, smoking, and pre-pregnancy history of BV as factors, whereas the final model published did not. The results presented here were calculated using the implemented risk score system. These results were subsequently recalculated using the published risk scoring system; any differences are noted in the text. Starting from a field of 44 potential risk factors, the BV risk scoring system was developed using bivariate analyses, logistic regression modeling, and receiver operating characteristic (ROC) curves. 10 Data recorded at each of the two screening assessments were: risk score results, clinical diagnosis of BV or not, clinical results for each of the four Amsel criteria, treatment if clinically diagnosed with BV, weight, date of visit, and gestational age. Height, age, parity, Hispanic ethnicity, African-American race, sickle cell disease, and pre-pregnancy history of BV were recorded at the first visit only. All data were recorded on a single page, as shown above, which was printed as a three-part carbonless form. One page was submitted to the researchers after the first risk score assessment, the second page was submitted after the second risk score assessment, and the third page remained in the woman's medical chart. The women were not asked to self-report symptoms. A normal discharge, as recorded by the physician, served as a surrogate for being asymptomatic.
The clinical protocol differed slightly in the two health departments. In Wake County, if the score was 3 or greater, the clinician used the Amsel criteria to diagnosis BV, according to their usual clinical procedure. If the risk score was less than 3, BV was only assessed clinically (''wet prep'') if the woman had symptoms of BV. This protocol is how the authors envisioned the actual implementation of the scoring system to work in a typical obstetrics clinic. In Catawba County, the protocol was revised such that the clinicians applied the Amsel criteria to all women regardless of the BV risk score. Because of the different protocols and its potential impact on the results, we have elected to separate the results by county health department in this manuscript.
In both prenatal clinics, women were treated for BV if they were diagnosed positive for BV, based on the clinic's wet prep testing, as detailed above.
Differences between the two county health departments were analyzed with two sample t-tests if the variable of interest was continuous and normally distributed (pooled methods if the variances were equal; Cochran method if the variances were unequal), Wilcoxon two-sample tests if the variable was continuous and not normally distributed, and w 2 tests if the variable was categorical. Sensitivity and specificity of the risk score to correctly identify women with Gram stain-confirmed BV were calculated for varying cutpoints of the total risk score. Likelihood ratios for multiple levels, as opposed to a dichotomy, of the total risk score were calculated according to Sackett et al. 11 The likelihood ratio for a positive test result is (sensitivity/1Àspecificity) in the test result range of interest. The proportion of women with normal discharge was calculated, and among these women, the proportions of elevated risk scores and true BV were determined. Among women with true BV, the proportion of asymptomatic cases was determined. All results were rerun with the published BV risk score algorithm, 10 and differences are noted in the text. ROC curves were drawn and the area under the curve (AUROC) was calculated parametrically. In order to assess the generalizability of the results to different populations, we repeated the ROC and AUROC analyses for varying subpopulations, such as only nulliparous women. All statistical analyses were conducted with SAS software (Cary, NC, USA).
RESULTS
The demographic profiles of the two samples are shown in Table 1 . The mean age of the pregnant women was 23 years in both study sites. The proportion of women of black race was greater in the The distribution of total risk scores (screening 1) by county health department is shown in Figure 1 . At the first assessment, the mean scores were 3.8 and 3.6 in Wake and Catawba, respectively (statistically similar distributions). At the second assessment, the Wake scores were lower than in Catawba (mean scores 2.7 and 3.8, respectively, Wilcoxon p<0.002). The most common score values at the first visit were 0 and 6, which correspond to no risk factors without or with a high vaginal pH, respectively.
The proportion of women with Gram-stained-confirmed BV was 26 to 31% at the first assessment and 12 to 14% at the second assessment in the two health departments ( Table 2 ). Approximately half of the women scored 3 or greater at each assessment using the BV PIN Points algorithm. If the population was restricted to women whose PIN Points score was over 3, 4 or 5, the proportion of true BV cases would be over 50% at the first prenatal visit, and between 22 and 46% at the second visit.
At the first prenatal visit, the sensitivity of the risk score to predict the true BV cases was 92% using a risk score of 3 or greater, and only dropped to 87% with a risk score of 5 or greater (Table 3) . At the second screening visit in the early third trimester, the sensitivity of the risk score ranged from 84 to 94%, depending on the health department and the cutoff value used for the risk score (3, 4 or 5). The specificity was lower than the sensitivity, as desired for this screening tool. The specificity at the first prenatal visit was approximately 67% using a risk score of 3 or greater, and increased to 72% (Catawba County) and 78% (Wake County) using a risk score of 5 or greater. At the second screening visit, the specificity was slightly lower than at the first prenatal visit (64% in Wake County and 53% in Catawba County) using a risk score of 3, and increased 10 to 20 percentage points using a risk score of 5 (84% in Wake County and 63% in Catawba County). For the two county health departments combined, the positive likelihood ratios (Table 4 , LR þ ) show that a woman with a total risk score of 6, 7, or 8 has a 3.3 times increased likelihood of having BV at the screening visit as opposed to not having BV. A woman with a total risk score at the level of 9 or greater has a 7.3 times increased likelihood of having BV. These positive likelihood ratios were quite similar between the first and second BV screenings (3.1 and 6.7 for the first screening and 3.6 and 7.2 for the second screening, respectively, for the risk score levels 6-8 and Z9). There were insufficient numbers of women with individual risk scores of 3, 4 or 5 to subdivide that risk score level. The LR þ for the individual risk scores of 6, 7 and 8 were 3.2, 2.9, and 4.2, respectively.
The Catawba County Health Department was the only location that assessed the presence of a vaginal discharge for all pregnant women. (In Wake County, only women who had a risk score of 3 or greater were assessed for vaginal discharge and wet preparations). Among the 200 Catawba women who were seen for a first prenatal care visit regardless of whether they had a second BV risk score assessment (five women were missing vaginal smears or the slides were broken in transit), 64.5% (129/200) of the women had a normal discharge at the first prenatal visit, and of these, 17.1% (22/129) had true BV based on the Gram-stained slide (Figure 2 ). This asymptomatic group of women who truly had BV at their first prenatal visit represents 11.0% (22/200) of the Catawba cohort. Of the women with BV, 42.3% (22/52) were asymptomatic. In total, 77% of these asymptomatic true BV cases (17/22) had a risk score Z3, and 100% of the symptomatic true BV cases had a risk score Z3 (30/30). African-American women with BV at their first prenatal care visit were less likely to be asymptomatic than non-black women (Fisher's exact test p ¼ 0.05, 17 vs 50%, respectively). There was some suggestion that Hispanic women with BV were more likely to be asymptomatic than non-Hispanic women (Fisher's exact test, p ¼ 0.09, 67 vs 35%, respectively). There was no difference in the proportion of asymptomatic cases by smoking status or parity.
The AUROC was 0.863 at the first screening (combined health departments), 0.846 at the second screening (Figure 3) , and 0.851 when both screening visits were combined. Because these values are similar, we combined the screening visits for the remainder of our ROC analysis. We calculated the AUROC with subsets of our population ( Table 5 ). The AUROC value was highest for the women with the largest body mass index (0.905).
Using the published BVPP risk score algorithm instead of the implemented risk score factors, the risk scores themselves were approximately 1 point lower due to fewer factors in the published algorithm. The only notable difference in our results was a higher specificity at each total risk score level, due to the fact that there were fewer women at each total score level with the published algorithm since the scores themselves were one point lower on average. For example, a risk score Z3 in Wake County had specificities of 67.0 and 63.9% at the first and second assessments, respectively. With the published risk score algorithm, the corresponding specificities were 81.6 and 87.8%. Sensitivity declined by approximately 5 percentage points with the published algorithm. For Wake County, the sensitivities at the two assessments were 91.5 and 86.5% with the implemented scoring algorithm, vs 86.6 and 81.1% with the published algorithm.
SIGNIFICANCE
In this population of women receiving obstetrical care through the public health department, Gram-stained-confirmed BV was found in 29% of the women at their first prenatal care visit and in 13% of the patients early in the third trimester. These results are similar to those reported in the literature: Hay et al. 12 found 21% of pregnant women in a London private clinic (n ¼ 266 with serial measurements) had Gram-stain confirmed BV at their first prenatal visit (mean gestational age 14 weeks), 12.8% had BV at the second assessment (mean gestational age 29.0 weeks), and 14.3% had BV at the third assessment (mean gestational age 36.4 weeks).
At the first prenatal visit, the sensitivity of the risk score to predict BV was 92% using a risk score Z3, and only dropped to 87% with a risk score Z5. At the second screening, the sensitivity ranged from 84 to 94%. The specificity at the first prenatal visit was approximately 67% using a risk score Z3, and increased to an average of 76% using a risk score Z5. A high sensitivity is more desirable than a high specificity in a risk scoring system such as BV PIN Points. The risk scoring system is meant to highlight women most at risk for BV, so asymptomatic cases can be better identified. A low specificity is acceptable as long as the risk scoring system achieves its objective of reducing the clinical tests performed on disease-free individuals.
The likelihood ratio results show the predictive strength of the risk score at multiple levels, as opposed to the dichotomy in risk score results that the sensitivity and specificity measures superimpose. The likelihood of having BV increases dramatically with risk scores of 6 or greater as opposed to 5 or less. The value of the likelihood ratios, as opposed to the sensitivity and specificity, depends on the perspective of the clinic. We anticipate that most readers of this report will want to identify women at increased risk of having antenatal BV so that further testing can be conducted on that subset of patients rather than universal screening. In this instance, a high sensitivity and moderate specificity would be the target, rather than high specificity and high positive likelihood ratios. Alternatively, if the clinician wants to identify women with the highest likelihood of having BV so that they can be treated without having to conduct further testing, then the clinician should select a high total risk score (e.g., over 6 or over 9) that corresponds to a high positive likelihood ratio.
The AUROC curve in practice is higher in this real world implementation than in the original published risk score analysis (0.851 vs 0.811). 10 We anticipate the risk score to be equally effective in differing clinic populations, since the AUROC was similar when we restricted our population to various subpopulations (nonblack women, women with no history of BV, symptomatic women, and nulliparous women).
We previously published an algorithm for identifying obstetrical patients at increased risk for BV. 10 That publication found that a total risk score Z4 jointly maximized the sensitivity and specificity at approximately 77%. In practice through this implemented algorithm (with more factors than the final published algorithm), the overall sensitivity at a total risk score Z4 was 88.4% and the specificity was 72.7%, which are higher/lower, respectively, than the 77% figures published with the original algorithm. (Redoing our analysis using the published scoring algorithm, we found sensitivity and specificity of 87.3% and 79.8% at a total risk score Z4, both of which are higher than the 77% published with the original algorithm.) So the risk score upon implementation did slightly better than originally projected. Our proportion of true BV cases with a normal discharge (42%) is similar to the literature on asymptomatic BV in nonpregnant populations. (Since an increased vaginal discharge and/or vaginal odor are the most likely symptoms reported by women with BV (65%) and a homogeneous vaginal discharge is the most common clinical sign apparent to doctors without administration of a test (69%), 4 we used a normal discharge as a surrogate for being asymptomatic.) Amsel et al. 3 studied approximately 400 college students, and found that 46% of those with BV were asymptomatic. Eschenbach 4 found 35% of BV cases were asymptomatic from a population of 640 patients in a sexually transmitted disease clinic. Corresponding figures from pregnant women were not located. No known prior research has examined whether or not the likelihood of symptoms among true BV cases differs by patient characteristics. We found that African-American women were more likely to have a symptomatic case, while neither smoking nor parity impacted the presence of symptoms.
There are several strengths to this study. First, this was a prospective study that included all women seen for prenatal care in two clinics. Second, the inclusion of two clinics with ethnically diverse populations help to make our findings representative of women in the US who receive medical care through the public health care system. Importantly, the proportion of African-American women differed significantly between the health departments and yet the risk score performed equally well in each clinic. Our primary study limitation was the lack of self-reported urogenital symptoms, although clinicians did record if the woman had an abnormal discharge.
These asymptomatic women are of particular interest to us because they would not be screened for BV under current clinical practice guidelines. 13 The risk score is most valuable to these women, since it is a tool to identify women at increased risk of having BV during their pregnancy. With the American College of Obstetricians and Gynecologists policy of not universally screening asymptomatic cases, clinicians who want to diagnose and treat these asymptomatic cases can benefit from the risk scoring algorithm. The risk score was very useful for identifying women with asymptomatic BV: 77% of women who had BV and were asymptomatic had a risk score Z3. (While the risk score would not be needed to diagnose symptomatic cases, it is interesting to note that all of the symptomatic BV cases had a risk score Z3.) BV during pregnancy is clearly an important condition since it is associated with preterm delivery (approximately 2.2 metaanalysis odds ratio 14 ) , amniotic fluid infection (relative risk ¼ 1.5 15 ), and post cesarean delivery endometritis (adjusted odds ratio ¼ 5.8 16 ). With BV prevalences during pregnancy that range from 6 to 32%, 2 the public health and economic impact of early detection and treatment is sizeable. 17 Symptomatic cases of BV will be identified and treated, but asymptomatic cases will be missed without prenatal clinic screening programs. A BV risk scoring tool can be very useful for the typical clinic as an alternative to universal screening for this important antenatal condition.
